Patents by Inventor Andrew Herr

Andrew Herr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ATTENUATING AN IMMUNE RESPONSE BY INHIBITION OF BFL1
    Publication number: 20230131243
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: December 19, 2022
    Publication date: April 27, 2023
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Methods of attenuating an immune response by inhibition of BFL1
    Patent number: 11541073
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: January 3, 2023
    Assignee: Children's Hospital Medical Center
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Methods and products for adverse effects of air travel, jet lag, or a change to a sleep wake timing cycle
    Patent number: 11419849
    Abstract: Methods and products are provided for preventing or reducing adverse effects of air travel, jet lag, and shift switching. Doses of antioxidant, anti-inflammatory, mitochondrial support, circadian shift support, and/or other agents are administered to or by the subject at selected times, and the subject sleeps or refrains from sleep, and/or is exposed to or protected from light, for selected times.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: August 23, 2022
    Assignee: KITT BIO, INC.
    Inventor: Andrew Herr
  • COMPOUNDS USEFUL FOR INHIBITING BFL1 AND THEIR USE IN THERAPY
    Publication number: 20220249437
    Abstract: The disclosure provides compounds of Formula I and their use in methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: July 9, 2020
    Publication date: August 11, 2022
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman
  • Suppressing IgE-Mediated Allergy by Desensitization with Monovalent Anti-FCeR1a Monoclonal Antibody
    Publication number: 20210371519
    Abstract: A monovalent monoclonal antibody is provided, the antibody including one light chain, one heavy chain, and one truncated heavy chain, wherein the truncated heavy chain lacks a variable domain and a CH1 domain and wherein the antibody specifically binds an epitope of Fc?RI?. Also provided are methods of desensitizing a subject to an allergen, methods of treating an allergy, and methods of preventing an allergic reaction in a subject having an allergy.
    Type: Application
    Filed: September 20, 2019
    Publication date: December 2, 2021
    Inventors: Fred Finkelman, Suzanne Morris, Marat Khodoun, Crystal Potter, Elizabeth Angerman, Andrew Herr, Matthias Peipp
  • METHODS OF TREATMENT BY INHIBITION OF BFL1
    Publication number: 20210113604
    Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.
    Type: Application
    Filed: January 14, 2019
    Publication date: April 22, 2021
    Inventors: David A. Hildeman, Andrew Herr, Suhas G. Kallapur, Jarek Meller, Alexander Thorman